Diabetes Type 3, which is regarded as “brain specific,” is not completely understood and remains a mystery. Diagnosis and treatments remain in the early stages, and more studies are required in order to fully understand how to help those with diabetes Type 3 as well as its connection to Alzheimer’s and dementia. However, a new product called CinGx may stimulate an insulin receptor protein which can assist in the treatment of Type 3 Diabetes, Alzheimer’s disease (AD) and levels of dementia. Diabetes increases the risk of Alzheimer’s disease by up to 65%.
Dr. William Klein, Neurobiology Professor at Northwestern University, and Dr. Marcus Cantillon, American Board Certified Neurologist and Psychiatrist state:
“We’re intrigued by the claim that insulin receptor protein tyrosine kinase might be stimulated by Allegiance’s formulation. DM (Diabetes) is one of the clear metabolic risk factors for AD, perhaps through insulin signaling or secondary cardiovascular effects. After rosiglitazone and other failures, there are no metabolic treatments in sight for AD that are effective and/or do not have serious side effects. Therefore insulin receptor protein tyrosine kinase treatment for Type 3 diabetes might represent a new opportunity for long term safe prevention of AD.”
It has recently been discovered that the brain produces insulin, and that the lack of insulin and high blood glucose are major factors impacting brain function negatively, thereby increasing the incidence and severity of Alzheimer’s and Dementia, a condition known as Type 3 Diabetes.
The American Diabetes Association notes that there isn’t a “standard definition” for diabetes Type 3, though it’s sometimes called “double diabetes” because it has been used to describe those with Type 1 diabetes who additionally shows signs of insulin resistance (the major symptom of Type 2 diabetes). Type 3 diabetes also has been used to describe those with Type 1 diabetes who become insulin-resistant over time. In some cases, taking insulin-sensitizing drugs may be beneficial.
Diabetes Type 3 is a dangerous diabetes hybrid that was first discovered in 2005. A study, which was conducted at Brown University Medical School, suggests the brain produces insulin in a way that’s similar to the pancreas. A problem with insulin production in the brain is thought to result in the formation of protein plaque, not unlike that which is found among suffers of Type 1 (insulin-dependant) and Type 2 diabetes (insulin-resistant).
However, in the case of diabetes Type 3, plaque appears in the brain and leads to memory loss and problems forming memories.
When it comes to the body, insulin is responsible for helping to convert food to energy. The brain uses insulin, too, but it’s thought insulin’s primary purpose in the brain is to form memories at synapses (the spaces where cells in the brain communicate). Neurons save space for insulin receptors; insulin makes way for memories to form. In order for the brain to keep making more brain cells, it needs insulin. When insulin receptors flee, as is the case with sufferers of diabetes Type 3, the brain does not receive the energy it needs to form memories.
David Solomon, President of Allegiance, which developed CinGx says:
“We are fortunate for the support of Dr. Klein and Dr. Cantillon, both leaders in the scientific research focusing on Alzheimer’s and Dementia. CinGx represents an opportunity similar to probiotics in yogurt.”
Insulin may prevent or slow memory loss among those with Alzheimer’s disease by protecting the synapses that form memory. Those with the disease tend to have lower insulin levels and are insulin-resistant. The reason memory fails when insulin shortage occurs is because amyloid beta-derived diffusible ligands (ADDLs) destroy the receptors in the brain that typically are reserved for insulin, thus making the receptors insulin-resistant. Without the space for insulin, receptors cannot connect, and memory loss occurs.
Sources: Allegiance Equity Corporation and The Lance Armstrong Foundation
Written by Sy Kraft, B.A.